¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lethal gene"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gene family
    À¯ÀüÀÚ±º
  • gene frequency
    À¯ÀüÀÚºóµµ
  • gene genetics
    À¯ÀüÀÚÀ¯ÀüÇÐ
  • gene imbalance
    À¯ÀüÀÚºÒÆòÇü
  • gene map
    À¯ÀüÀÚÁöµµ
  • gene mapping
    À¯ÀüÀÚÀ§Ä¡ÁöÁ¤, À¯ÀüÀÚÁöµµÀÛ¼º
  • gene pool
    À¯ÀüÀÚÇ®
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ
  • gene redundancy
    À¯ÀüÀÚÁߺ¹
  • gene regulation
    À¯ÀüÀÚÁ¶Àý
  • gene replacement
    À¯ÀüÀÚ±³È¯
  • gene segment
    À¯ÀüÀÚÁ¶°¢
  • gene splicing
    À¯ÀüÀÚ½ºÇöóÀ̽Ì, À¯ÀüÀÚÀß¶óÀÌÀ½
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
  • gene transfection
    1. À¯ÀüÀÚÀü´Þ°¨¿° 2. À¯ÀüÀÚÇÙ³»ÁÖÀÔ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gene map
    À¯ÀüÀÚÁöµµ
  • gene mapping
    À¯ÀüÀÚÀ§Ä¡ÁöÁ¤, À¯ÀüÀÚÁöµµÀÛ¼º
  • gene pool
    À¯ÀüÀÚÇ®
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ
  • gene redundancy
    À¯ÀüÀÚ¿©À¯
  • gene regulation
    À¯ÀüÀÚÁ¶Àý
  • gene replacement
    À¯ÀüÀÚ±³È¯
  • gene segment
    À¯ÀüÀÚÁ¶°¢
  • gene transfection
    À¯ÀüÀÚÀü´Þ°¨¿°
  • gene transfer
    À¯ÀüÀÚÀü´Þ
  • gene translocation
    À¯ÀüÀÚÀüÀ§
  • gonosomal gene
    ¼º¿°»öüÀ¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ÀûÇÕÇ׿øÀ¯ÀüÀÚ
  • hox gene
    Ȥ½ºÀ¯ÀüÀÚ
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene conversion
    À¯ÀüÀÚÀüȯ.
  • gene defect
    À¯ÀüÀÚ°á¼Õ<--°á¿©>
  • gene deletion
    À¯ÀüÀÚ°á½Ç<--»èÁ¦
  • gene, mutator
    º¯ÀÌÀ¯¹ßÀ¯ÀüÀÚ
  • gene, operator
    ÀÛµ¿À¯ÀüÀÚ
  • gene, regulatory
    Á¶ÀýÀ¯ÀüÀÚ
  • gene, repressor
    ¾ïÁ¦À¯ÀüÀÚ
  • gene, structural
    ±¸Á¶À¯ÀüÀÚ
  • gene, suppressor
    ¹ßÇö¾ïÁ¦À¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ÀûÇÕ¼º À¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ÀûÇÕÀ¯ÀüÀÚ.
  • immediate early gene
    Á¶±â ¹ßÇö À¯ÀüÀÚ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • tumor lethal dose
    Á¾¾çÄ¡»ç·®(ðþåËöÈÞÝåÖ)
  • additive gene
    »ó°¡À¯ÀüÀÚ(ßÓÊ¥ë¶îîí­).
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • aniridia,pax-6 gene
    PAX-6 À¯ÀüÀÚ(¡­ë¶îîí­)
  • apc gene
    APC À¯ÀüÀÚ(¡­ë¶îîí­)
  • atk gene
    atk À¯ÀüÀÚ(¡­ë¶îîí­)
  • autosomal gene
    º¸Åë¿°»öüÀ¯ÀüÀÚ
  • bcg gene
    bcg À¯ÀüÀÚ(¡­ë¶îîí­)
  • bcl gene
    bcl À¯ÀüÀÚ
  • bcr-c-abl gene
    bcr-c-abl À¯ÀüÀÚ
  • beta-globin gene
    º£Å¸±×·ÎºóÀ¯ÀüÀÚ(¡­ë¶îîí­)
  • c4a gene
    C4A À¯ÀüÀÚ (¡­ë¶îîí­)
  • calcitonin-gene related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • complementary gene
    º¸Á·À¯ÀüÀÚ(ÜÍðëë¶îîí­), º¸Ã¼À¯ÀüÀÚ.
  • contiguous gene syndrome
    Á¢Ã˼º À¯ÀüÀÚ ÁõÈıº(ïÈõºàõë¶îîí­ñøý¦ÏØ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gene amplification
    À¯ÀüÀÚ ÁõÆø(ë¶îîí­ñòøë)
  • gene bank
    À¯ÀüÀÚ ÀºÇà(ë¶îîí­ëÞú¼)
  • gene cloning
    À¯ÀüÀÚ(ë¶îîí­) Ŭ·Î´×
  • gene cluster
    À¯ÀüÀÚ(ë¶îîí­) ¼ÛÀÌ
  • gene conversion
    À¯ÀüÀÚ Àüȯ(ë¶îîí­ï®üµ)
  • gene dosage
    À¯ÀüÀÚ ·®(ë¶îîí­Õá)
  • gene duplication
    À¯ÀüÀÚ º¹»ç(ë¶îîí­ÜÜÞÐ)
  • gene expression
    À¯ÀüÀÚ ¹ßÇö(ë¶îîí­Û¡úÞ)
  • gene family
    À¯ÀüÀÚ Á·(ë¶îîí­ðé)
  • gene frequence
    À¯ÀüÀÚ ºóµµ(ë¶îîí­ÞºÓø)
  • gene fusion
    À¯ÀüÀÚ À¶ÇÕ(ë¶îîí­ë×ùê)
  • gene hypothesis
    À¯ÀüÀÚ ¼³(ë¶îîí­àã)
  • gene insertion
    À¯ÀüÀÚ »ðÀÔ(ë¶îîí­ßºìý)
  • gene library
    À¯ÀüÀÚ(ë¶îîí­) ¶óÀ̺귯¸®
  • gene linkage
    À¯ÀüÀÚ ¿¬°ü(ë¶îîí­Ö¤Î¼)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ELD egg lethal dose
ILC ichthyosis linearis circumflex; incipient lethal concentration
LA50 total body surface area of burn that will kill 50% of patients (lethal area)
LC Laennec cirrhosis; Langerhans cell; late clamped; large chromophobe; lecithin cholesterol acyltransf...
LC50 median lethal concentration
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MLC Minimal lethal concentrations
MLC Minimum Lethal Concentration
MLD Minimum Lethal Dose
PLD Potentially lethal damage
PLDR Potentially lethal damage repair
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • virulence gene
    µ¶¼º À¯ÀüÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
variable gene <molecular biology> Those regions in the amino acid sequence of both the heavy and the light chains of immunoglobulins where there is considerable sequence variability from one immunoglobulin to other of the same class, in contrast to constant sequence (C) regions. The V regions are associated with the antigen binding areas. They contain hypervariable regions of particularly high sequence diversity.
(18 Nov 1997)
gap gene <molecular biology> Segmentation genes involved in specifying relatively coarse subdivisions of the embryo.
They are expressed sequentially in development between egg polarity genes and pair rule genes. In Drosophila, there are at least three such genes, for example Kruppel.
(18 Nov 1997)
gene <cell biology, molecular biology> Originally defined as the physical unit of heredity, it is probably best defined as the unit of inheritance that occupies a specific locus on a chromosome, the existence of which can be confirmed by the occurrence of different allelic forms.
Genes are formed from DNA, carried on the chromosomes and are responsible for the inherited characteristics that distinguish one individual from another. Each human individual has an estimated 100,000 separate genes.
Given the occurrence of split genes, it might be redefined as the set of DNA sequences (exons) that are required to produce a single polypeptide.
(09 Oct 1997)
gene activation The process of activation of a gene so that it is expressed at a particular time. This process is crucial in growth and development.
(05 Mar 2000)
gene amplification <molecular biology> Selective replication of DNA sequence within a cell, producing multiple extra copies of that sequence. The best known example occurs during the maturation of the oocyte of Xenopus, where the set (normally 500 copies) of ribosomal RNA genes is replicated some 4,000 times to give about 2 million copies.
(18 Nov 1997)
gene bank A group of genes which are coordinately controlled.
(09 Oct 1997)
gene cloning <molecular biology> The insertion of a DNA sequence into a vector that can then be propagated in a host organism, generating a large number of copies of the sequence.
(18 Nov 1997)
gene cluster A set of closely related genes that code for the same or similar proteins and which are usuallygrouped together on the same chromosome.
(09 Oct 1997)
gene conversion <molecular biology> A phenomenon in which alleles are segregated in a 3:1 not 2:2 ratio in meiosis. May be a result of DNA polymerase switching templates and copying from the other homologous sequence or a result of mismatch repair (nucleotides being removed from one strand and replaced by repair synthesis using the other strand as template).
(18 Nov 1997)
gene deletion The total loss (or absence) of a gene. Gene deletion plays a role in birth defects and in the development of cancer.
(12 Dec 1998)
gene disorder Hereditary disorder caused by a mutant allele of a single gene (e.g., Duchenne muscular dystrophy, retinoblastoma, sickle cell disease).
Compare polygenic disorders.
(05 Mar 2000)
gene disruption Use of both in vitro and in vivo recombination to substitute an easily selected mutant gene for a wild-type gene.
(09 Oct 1997)
gene divergence The difference (expressed as a percentage) in the nucleotide sequencesbetween two related genes that developed from the same ancestral gene.
(09 Oct 1997)
gene dosage <molecular biology> Number of copies of a particular gene locus in the genome, in most cases either one or two.
(18 Nov 1997)
gene dosage compensation The putative mechanism that adjusts the X-linked phenotypes of males and females to compensate for the haploid state in males and the diploid state in females. It is now largely ascribed to lyonization which compensates the mean of the dose but not its variance, which is greater in females.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á